Study on pharmacokinetics of fluorouracil sustained release implant in the treatment with malignant pleural or peritoneal effusions
10.3969/j.issn.1001-6821.2009.04.003
- VernacularTitle:氟尿嘧啶植入剂治疗恶性胸腹水的药代动力学研究
- Author:
Yan-Yan HONG
1
;
Zhen-Dong CHEN
;
Ming-Jun ZHANG
;
Min YU
;
Xiu-Wei WU
;
Rui-Ping YE
;
Li-Wei LIU
;
Yang YANG
Author Information
1. 安徽医科大学附属第一医院
- Keywords:
fluorouracil sustained release preparations;
pharmacokinet-its;
malignant pleural effusions;
malignant ascites
- From:
The Chinese Journal of Clinical Pharmacology
2009;25(4):298-301
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the pharmacokinetics of fluoroura-cil (5-Fu) sustained release implant (FSRI) administered intrapleural-ly or intraperitoneally in the patients with malignant pleural effusions or ascites. Methods Twelve patients with moderate or large malignant pleural effusions or ascites were enrolled. FSRI was administered intra-pleurally or intraperitoneally at a fixed dosage of 1500 mg. The pleural or peritoneal effusions and plasma samples were obtained before and after administration. Concentrations of 5-Fu were measured by HPLC. Phar-macokinetic parameters were calculated. Results In the pleural(perito-neal) effusions, 5-Fu concentration was significantly higher than that in plasma (P<0.05 ). Drugs released slowly, and the concentrations in the effusions were still more than the effective concentration at the 15th day.Conclusion When administered intrapleurally or intraperitoneally flu-orouracil sustained release implant had a long elimination and high localconcentrations.
